Genetic Diseases, Inborn Clinical Trial
Official title:
The Histological and Genetic Investigation of Cells, Fluid and Tissue in the Uterine Cavity, Using the Uterine Irrigation Method, in Patients Who Suffer From Unexplained Infertility and Hereditary Genetic Disease, and Who Require PGD Scans.
The study will involve up to 30 pairs of male and female sexually intimate partners who are carriers for a genetic disease (e.g Sickle Cell Disease or Thalassemia) and at high risk of transmitting the gene. The female partner will be superovulated to mature multiple oocytes which can be fertilized, inseminated with her partner's sperm through intra-uterine insemination (IUI). Four to six days after IUI, the female partner will undergo a non-surgical uterine lavage procedure to recover preimplantation embryos.
The study is a prospective, single center, single-arm study to evaluate healthy cells which
do not carry illnesses, by collecting and performing the histological and genetic analyses
of blastocysts, endometrial tissue and cells, which have been formed in the uterus, without
any burden of the morbidity and mortality caused by the oocyte collection process, and which
thereby have not been subjected to any iatrogenic intervention, with uterine lavage.
The study will involve up to 30 pairs of male and female sexually intimate partners who are
carriers for a genetic disease (e.g Sickle Cell Disease or Thalassemia) and at high risk of
transmitting the gene.
The female partner will be superovulated to mature multiple oocytes which can be fertilized,
inseminated with her partner's sperm through intra-uterine insemination (IUI). Four to six
days after IUI, the female partner will undergo a non-surgical uterine lavage procedure to
recover preimplantation embryos.
Following lavage, a GnRH antagonist will be administered to cause lysis of multiple corpora
lutea to mitigate risk of hyperstimulation from the use of fertility medication and reduce
the risk of ectopic pregnancy should the lavage procedure not recover all preimplantation
embryos.
Recovered preimplantation embryos may be screened for aneuploidy and genetic disease, then
cryopreserved for potential future use by the subjects and the Investigator separate from
the purpose of this study.
Each subject participates in the trial for up to 10-20 weeks.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Active, not recruiting |
NCT03655678 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia
|
Phase 2/Phase 3 | |
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Recruiting |
NCT03587155 -
Study on the Mechanism of Neurodevelopment Dysplasia of Fetal Brain Caused by ASNS Gene Mutation
|
||
Not yet recruiting |
NCT05070234 -
Genetic Diagnosis and Human Growth Hormone Treatment in Small for Gestational Age Children With Short Stature
|
||
Completed |
NCT00458055 -
High-Density Lipoprotein (HDL) Treatment Study
|
N/A | |
Terminated |
NCT01963650 -
Natural History Study of Children With Metachromatic Leukodystrophy
|
||
Recruiting |
NCT05356195 -
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
|
Phase 3 | |
Completed |
NCT03721458 -
Whole Genome Sequencing in the Neonatal Intensive Care Unit
|
||
Not yet recruiting |
NCT06337864 -
Evaluating the Efficacy and Safety of Large Neutral Amino Acids in the Treatment of Classical Phenylketonuria
|
N/A | |
Completed |
NCT02884063 -
Utilizing Free DNA in Embryo Culture for PGT
|
||
Completed |
NCT00477594 -
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
|
Phase 2 | |
Completed |
NCT03406780 -
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT01826487 -
Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
|
Phase 3 | |
Terminated |
NCT02090959 -
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
|
Phase 3 | |
Recruiting |
NCT05126758 -
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
|
Phase 3 | |
Completed |
NCT03627767 -
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
|
Phase 3 | |
Completed |
NCT03179631 -
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
|
Phase 3 | |
Completed |
NCT02429947 -
An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients
|
N/A | |
Completed |
NCT00607373 -
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
|
Phase 3 |